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Background/aim: Albumin is the most important protein synthesized by the liver. Posttranscriptional changes occur in the molecular
structure of albumin due to various factors and isoforms arise. Ischemic modified albumin (IMA) is one such isoform. This study was
conducted to evaluate serum IMA concentrations in patients with hepatitis B virus (HBV)-related chronic liver diseases.
Materials and methods: This study included 74 treatment-naive chronic hepatitis B patients, 25 patients with HBV-related cirrhosis,
and 49 healthy controls. Serum IMA concentration was measured spectrophotometrically using the albumin cobalt binding test.
Results: The mean IMA concentrations in the chronic hepatitis B group and healthy controls were 0.33 ± 0.11 ABSU and 0.27 ±
0.70 ABSU, respectively, and the difference was statistically significant (P < 0.001). Mean IMA/albumin ratios (IMAR) in the chronic
hepatitis B and control groups were 0.08 ± 0.04 and 0.06 ± 0.17, respectively, and the difference was also statistically significant (P <
0.001). Higher serum IMA concentrations and IMAR were detected in patients with advanced fibrosis.
Conclusion: Serum IMA concentration and IMAR are increased in patients with HBV-related chronic liver diseases and IMA and
IMAR are associated with the degree of liver fibrosis. IMA and IMAR may have potential use as noninvasive markers of fibrosis in
chronic hepatitis B patients.
Key words: Chronic hepatitis B infection, fibrosis, ischemia-modified albumin, IMAR

1. Introduction
Hepatitis B virus (HBV) infection is an important health
problem. The seroprevalence of hepatitis B surface antigen
(HBsAg) was previously reported to be 3.61% globally (1).
Approximately 600,000 people are estimated to die each
year due to HBV-related diseases and their complications.
Liver cirrhosis and hepatocellular carcinoma are the most
important HBV-related complications (2). Assessment
of the degree of necroinflammation and fibrosis in the
liver is crucial for treatment decisions and follow-up of
patients with HBV-related liver diseases. Hepatic fibrosis
was formerly considered as an irreversible course, but
data from recent studies suggest that fibrosis is a dynamic
process and it may regress if the underlying insult is treated
(3). As a consequence, the need for elucidating the changes
in fibrosis during disease course in patients with chronic
HBV infection has emerged, and this yielded studies
focused on noninvasive methods to evaluate liver fibrosis
* Correspondence: drmehmetasil@yahoo.com.tr

(4,5). Unfortunately, there is no optimal noninvasive
marker to determine liver inflammation and fibrosis
today, and liver biopsy still remains the gold-standard
method (6). Although liver biopsy is generally considered
to be safe, it is an invasive intervention and it may cause
several life threatening complications like bleeding, pain,
infection, and even death.
Albumin is the most important protein synthesized by
the liver, and it is the most secreted protein in extracellular
fluids, which constitutes 70% of plasma colloidal osmotic
pressure. For this reason, albumin has a key role in fluid
balance and distribution in the body (7). Moreover,
albumin binds to many molecules (metals, drugs, fatty
acids, etc.) in the circulation by various functional
regions in its structure, taking roles in transportation,
detoxification, and elimination of them from the body. The
amino-terminal end of albumin has the capacity to bind
metals like cobalt and nickel. Ischemia, hypoxia, increased
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free radicals, and acidosis associated with various diseases
result in changes in the molecular structure of albumin,
decreasing this metal ion-binding capacity. This new
isoform of albumin is called ischemic modified albumin
(IMA), and its serum levels can be measured (8–10).
Serum IMA levels and IMA/albumin ratio (IMAR) were
shown to increase in several diseases such as myocardial
ischemia, acute stroke, muscle ischemia, and bowel
ischemia (11–14). There are also studies in the literature
reporting increased serum IMA concentrations and IMAR
in chronic liver diseases of various etiologies (15–18).
In this study, we aimed to investigate serum IMA
concentration and IMAR in cirrhotic and noncirrhotic
chronic hepatitis B patients. Associations of IMA and
IMAR with liver biopsy findings were also evaluated in
order to determine the usability of IMA and IMAR as
noninvasive markers of fibrosis levels in HBV-related liver
diseases.
2. Materials and methods
Seventy-four chronic hepatitis B patients, 25 patients
with HBV-related liver cirrhosis, and 49 healthy controls
were enrolled in the study. Ethical approval of the study
protocol was obtained from the local ethics committee
of Necmettin Erbakan University, Meram Faculty of
Medicine, and written informed consent was obtained from
all participants. The chronic hepatitis B group consisted
of treatment-naive patients who were HBsAg-positive
for at least 6 months with active viral replication (HBV
DNA: >2000 IU/mL). Liver biopsy was performed for all
patients in the chronic hepatitis B group and the degree of
inflammation and/or fibrosis was graded using the Ishak
scoring system. On the other hand, liver biopsy was not a
must in the HBV-related cirrhosis group. HBsAg-positive
patients for whom cirrhosis was diagnosed with clinical,
laboratory, and radiological findings and patients with
Ishak stage 5/6 fibrosis in liver biopsies were included in this
group. Forty-nine age- and sex-matched healthy subjects
were included in the control group. Complete blood count,
serum aspartate and alanine aminotransferases, HBsAg,
anti-HBc IgG, and anti-HCV values were obtained for
each person in the control group to exclude any possible
liver disease. All of the participants were informed prior to
the study and provided signed informed consent. Patients
with known chronic diseases (malignancies, diabetes
mellitus, coronary artery disease, etc.), patients with
chronic liver diseases of any other etiology, and patients
with considerable alcohol consumption (>20 g/day for
males and >10 g/day for females) were not included in
the study. Patients with a history of albumin transfusion
within 30 days were also excluded from the study as it
might affect the IMAR.
Blood samples from patients were obtained early
in the morning after overnight fasting. Biochemical
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analyses of fasting blood glucose, bilirubin, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase (ALP), gamma-glutamyl transferase
(GGT), and albumin were performed in our hospital’s
laboratory with automated analyzers. Blood samples for
IMA were centrifuged for 5 min at 4 °C and 4000 rpm
and serum samples were immediately transferred to a
freezer to be stored at –80 °C until spectrophotometric
measurements were done.
IMA measurements were done by albumin cobalt
binding (ACB) test. In this test, cobalt (Co) is added to the
serum sample to measure the binding capacity of albumin.
Free cobalt is stained with a protein named dithiothreitol
(DTT) and spectrophotometric measurements are done.
DTT cannot react with the albumin that binds to Co. As
a consequence, the free Co amount also reflects the IMA
level (19). Serum IMA measurements were performed as
follows: 50 µL of 1 g/L cobalt chloride solution was added
to 200 µL of patient serum and kept at room temperature
for 10 min after a gentle shake. Then 50 µL of 1.5 g/L
DTT solution was added and mixed. After 2 min, 1 mL
of 9.0 g/L NaCl solution was added. Absorbances of test
mixtures were measured at 470 nm by a spectrophotometer
and calorimetric method. Results were obtained in
approximately 30 min and reported as absorbance units
(ABSU). IMAR was calculated using the following formula:
IMAR = IMA/serum albumin concentration (g/dL).
Chronic hepatitis B patients were further classified into
mild (group 1), moderate (group 2), and advanced fibrosis
(group 3) groups on the basis of liver histological findings;
patients with Ishak stage 1–2 fibrosis were included in
group 1 and patients with Ishak stage 3–4 fibrosis were
included in group 2. Patients with Ishak stage 5–6 fibrosis
and also patients for whom cirrhosis was diagnosed
with clinical, laboratory, and radiological findings were
included in group 3.
SPSS 16.0 was used for statistical analyses. Continuous
variables were presented as mean ± standard deviation.
Significance of the difference in more than two groups
was tested using one-way ANOVA tests for normally
distributed parameters and by Kruskal–Wallis test for
nonnormally distributed parameters. For comparisons
between two groups, the independent samples t-test and
the Mann–Whitney U test were used for normally and
nonnormally distributed parameters, respectively. Pearson
and Spearman rho tests were used for correlations between
numerical variables. P < 0.05 was considered as significant.
3. Results
The study group consisted of 56 (56.6%) male and 43
(43.4%) female subjects with a mean age of 47.9 ± 13.0
years (range: 16–73 years) and the control group included
49 patients with a mean age of 43.9 ± 9.8 years (range: 21–
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70 years), of whom 26 (53.1%) were males and 23 (46.9%)
were females. There were no significant differences
between the study and the control groups regarding age
and sex (P = 0.186 and P = 0.519, respectively).
Mean serum IMA concentrations in the chronic
hepatitis B group and healthy controls were 0.33 ± 0.11
ABSU and 0.27 ± 0.70 ABSU, respectively, and the
difference between the groups was statistically significant
(P < 0.001). Patients in the chronic hepatitis B group were
subclassified in three groups according to the degree of
fibrosis in liver biopsy specimens as previously described
to search for any possible association between mean serum
IMA concentration and the degree of liver fibrosis. Mean
IMA concentrations in group 1 (mild fibrosis), group 2
(moderate fibrosis), and group 3 (advanced fibrosis) were
0.29 ± 0.12 ABSU, 0.34 ± 0.10 ABSU, and 0.39 ± 0.13 ABSU,
respectively, and the difference between the groups was
statistically significant (P < 0.001) (Figure 1). Intergroup
comparisons revealed that the differences between the
control group and group 2 (P = 0.002), control group and
group 3 (P < 0.001), and group 1 and group 3 (P = 0.044)
were statistically significant.
Mean IMAR values in the chronic hepatitis B group
and healthy controls were 0.08 ± 0.04 and 0.06 ± 0.17,
respectively, and the difference between the groups was
statistically significant (P = 0.017). Mean IMAR in the
mild (group 1), moderate (group 2), and advanced fibrosis
(group 3) groups was 0.06 ± 0.03, 0.08 ± 0.03, and 0.13 ±
0.06, respectively, and the difference between the groups

was also statistically significant (P < 0.001) (Figure 2).
Intergroup comparisons revealed that the differences
between the control group and group 2 (P = 0.004),
control group and group 3 (P < 0.001), group 1 and group
2 (P = 0.043), and group 1 and group 3 (P < 0.001) were
statistically significant.
Demographic characteristics and laboratory data in
groups 1, 2, and 3 and the control group are summarized
in the Table.
Receiver operating characteristic (ROC) curves were
obtained in the chronic hepatitis B group for both IMA
and IMAR to differentiate patients with advanced fibrosis
from patients with mild and moderate fibrosis. The
computed area under the curve (AUC) was 0.692 (95%
CI: 0.578–0.806) for IMA and the specified cut-off value of
0.35 revealed 60.6% sensitivity and 72.4% specificity. On
the other hand, ROC analyses for IMAR revealed that the
computed AUC was 0.797 (95% CI: 0.693–0.902), and for
the specified cut-off value of 0.082 the calculated sensitivity
and specificity were 60.6% and 86.0%, respectively. ROC
curves for IMA and IMAR are summarized in Figure 3.
4. Discussion
Serum albumin is the most abundant protein in systemic
circulation, and it has antioxidant and immune modulatory
functions in addition to its primary oncotic function
(20). Several studies have shown that posttranscriptional
structural and subsequent functional alterations might
occur in the structure of albumin due to several factors

Figure 1. Serum IMA concentrations in mild, moderate, and advanced fibrosis groups
and the control group.
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Figure 2. IMAR in mild, moderate, and advanced fibrosis groups and the control group.

Table. Demographic characteristics and laboratory data of the study groups.
Group 1 (n = 48)
(mild fibrosis)

Group 2 (n = 28)
(moderate fibrosis)

Group 3 (n = 31)
(advanced fibrosis)

Control (n = 49)

P

Age (years)

47.44 ± 12.75

51.96 ± 11.89

52.35 ± 8.84

46.63 ± 10.16

0.051

IMA (ABSU)

0.29 ± 0.12 a, d

0.34 ± 0.10 a, b

IMAR

0.06 ± 0.01 a

0.08 ± 0.03 b

0.13 ± 0.06 c

0.06 ± 0.02 a, d

<0.001

Glucose (mg/dL)

107.77 ± 44.26

102.18 ± 30.23

100.60 ± 16.12

92.65 ± 18.78

0.246

Creatinine (mg/dL)

0.77 ± 0.14 a

0.73 ± 0.12

0.76 ± 0.24

0.74 ± 0.12

0.777

AST (U/L)

31.81 ± 25.01 a

41.70 ± 33.59 a, b

48.69 ± 37.54 b

19.82 ± 4.50 c

0.003

ALT (U/L)

47.48 ± 60.07 a

52.96 ± 54.95 a, b

36.17 ± 19.65 b

22.22 ± 15.33 c

0.022

GGT (U/L)

27.42 ± 21.75 a

40.65 ± 3.66 a

83.46 ± 85.37 b

19.50 ± 5.89 a

<0.001

ALP (U/L)

84.89 ± 25.49 a

84.18 ± 35.00 a

112.38 ± 39.30 b

83.00 ± 23.51 a

0.004

Total bilirubin (mg/dL)

0.91 ± 0.62 a

0.92 ± 0.33 a

2.22 ± 2.01 b

0.44 ± 0.20 c

<0.001

Direct bilirubin (mg/dL)

0.27 ± 0.16 a, c

0.33 ± 0.11 a

0.87 ± 0.91 b

0.17 ± 0.08 c

<0.001

Albumin (g/dL)

4.38 ± 0.33 a

4.12 ± 0.38 b

3.40 ± 0.66 c

4.38 ± 0.35 a

<0.001

Leukocyte (mm )

7.10 ± 2.05 a

7.25 ± 1.97 a

5.04 ± 2.02 b

7.48 ± 1.60 a

<0.001

Hemoglobin (g/dL)

14.35 ± 1.88 a

14.38 ± 1.95 a

12.60 ± 2.57 b

14.14 ± 1.53 a

0.001

Thrombocyte (mm3)

254.50 ± 75.30 a, d

226.00 ± 57.98 a

97.87 ± 47.32 b

270.20 ± 52.04 c, d

<0.001

3

0.39 ± 0.13 b

0.27 ± 0.07 c, d

<0.001

IMA: Ischemic modified albumin, IMAR: ischemic modified albumin ratio, AST: aspartate aminotransferase, ALT: alanine
aminotransferase, GGT: gamma-glutamyltransferase, ALP: alkaline phosphatase. Values in rows followed by different letters are
significantly different.
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Figure 3. ROC curves for IMA and IMAR to differentiate patients with advanced
fibrosis from patients with mild and moderate fibrosis.

and new isoforms arise (21,22). These changes are minimal
under physiologic conditions. However, factors like
ischemia and oxidative stress cause increases in serum
concentrations of these isoforms. In chronic liver diseases,
in addition to the decreased synthesis of albumin by the
liver, concentrations of different albumin isoforms also
increase due to alteration of the microenvironment within
the liver or effects of several prooxidants. Some of these
albumin isoforms were shown to be related to ascites,
renal dysfunction, and bacterial infections in patients
with chronic liver diseases (21). On the other hand, it was
shown that serum concentration of naturally protected
native albumin was much lower than total serum albumin
concentration in cirrhotic patients and more importantly
this undamaged native albumin concentration was found to
be related to survival in patients with chronic liver diseases
(15). IMA is the most important isoform of albumin.
The findings of the current study can be summarized as
follows: serum IMA concentration and IMAR were higher
in patients with chronic hepatitis B and HBV-associated
liver cirrhosis when compared to healthy controls; both
serum IMA concentration and IMAR were higher in
patients with advanced fibrosis in the chronic hepatitis B
group; and IMAR predicted liver fibrosis better than serum
IMA concentration.

It is well known that the synthesis and functions of
albumin deteriorate in patients with liver failure (22). The
number of studies evaluating the association of serum
IMA concentration and IMAR with disease progression in
patients with chronic liver diseases is limited. In a study
conducted by Chen et al. (18) it was shown that serum
IMA concentration and IMAR were correlated with serum
bilirubin concentration and international normalized
ratio, both of which are well-known indicators of synthetic
dysfunction of the liver, in patients with chronic liver
diseases. They also reported that IMAR was associated
with Child–Pugh and MELD scores in cirrhotic patients.
In another study, Cakir et al. (16) reported that serum IMA
concentration and IMAR were higher in pediatric patients
with chronic liver diseases of various etiologies than in
healthy controls. It is also remarkable that both studies
suggested using IMAR rather than IMA in patients with
advanced liver diseases. We also agree that using IMAR
would be more appropriate in patients with advanced liver
diseases. Parallel to liver parenchymal failure, albumin
synthesis is decreased and serum albumin concentration
is low in these patients. As a consequence of low serum
albumin concentration, the cobalt binding capacity of
albumin also decreases. In this setting, the measured
serum IMA concentration would be higher than the actual
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serum concentration (15). Therefore, using the IMAR
would more accurately reflect the actual serum IMA levels
in patients with advanced-stage liver diseases.
Another important finding of this study was the
association among IMA, IMAR, and the degree of fibrosis
in liver biopsy samples in patients with chronic hepatitis
B. Serum IMA and IMAR levels were significantly higher
in patients with advanced-stage fibrosis than the ones with
lower grades of fibrosis. Although the studies mentioned
above also suggested the association of IMA and IMAR
with disease progression in patients with chronic liver
diseases of various etiologies, to our knowledge, there is no
other study in the literature showing the association among
serum IMA concentration, IMAR, and the degree of liver
fibrosis in liver biopsy samples in patients with chronic
hepatitis B. The results of this study also showed that
IMAR was more valuable than serum IMA concentration
to discriminate patients with mild and advanced fibrosis
and cirrhosis.
We think that one of the strong points of this study
is that it includes patients with various stages of liver
diseases of a common etiology. The etiological agent in

both the chronic hepatitis group and the cirrhosis patients
was chronic hepatitis B infection. On the other hand, the
major weakness of this study is that it is a cross-sectional
study and therefore it lacks serial measurements of IMA
in patient groups. Therefore, we suggest that further
prospective studies with adequate numbers of patients that
evaluate IMA measurements at different time points in
the course of chronic HBV infection would more clearly
demonstrate the association of serum IMA levels and
IMAR with disease progression and prognosis.
In conclusion, during the course of chronic liver diseases
several factors result in posttranscriptional structural
changes in albumin, and isoforms with unique biological
characteristics are produced. IMA is one of these isoforms.
Serum IMA concentration and IMAR increase in HBVassociated chronic liver diseases and correlate with the
degree of liver fibrosis. For this reason, we think that IMA
and IMAR may have the potential to be used as noninvasive
indicators of fibrosis. Nevertheless, further studies are
needed to better elucidate the roles and associations of IMA
and other isoforms with different clinical and laboratory
parameters during the course of chronic liver diseases.
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